CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Price, Quote, News and Overview
NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock
CDIO Quote and Key Statistics
CARDIO DIAGNOSTICS HOLDINGS
NASDAQ:CDIO (1/22/2025, 9:39:08 AM)
0.6277
+0.02 (+3.24%)
CDIO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -184.16% | ||
| ROE | -223.89% | ||
| Debt/Equity | 0 |
CDIO Performance and Technical Analysis
CDIO Ownership and Analysts
CDIO Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
About CDIO
Company Profile
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Company Info
CARDIO DIAGNOSTICS HOLDINGS
311 W. Superior Street, Suite 444
Chicago ILLINOIS US
Employees: 8
Company Website: http://www.cardiodiagnosticsinc.com
Investor Relations: https://cardiodiagnosticsinc.com/investors-sec-filings/
Phone: 18552269991
CDIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.66 | 297.41B | ||
| AMGN | AMGEN INC | 14.29 | 147.64B | ||
| GILD | GILEAD SCIENCES INC | 20.85 | 115.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 834.21 | 109.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.21 | 75.94B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.89B | ||
| NTRA | NATERA INC | N/A | 22.26B | ||
| BIIB | BIOGEN INC | 8.64 | 20.57B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.98B |